世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

免疫チェックポイント阻害薬市場レポート:タイプ別(CTLA-4阻害薬、PD-1阻害薬、PD-L1阻害薬)、流通チャネル別(病院薬局、小売薬局、オンライン薬局)、用途別(肺がん、膀胱がん、メラノーマ、大腸がん、ホジキンリンパ腫、その他)、地域別 2024-2032


Immune Checkpoint Inhibitors Market Report by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin Lymphoma, and Others), and Region 2024-2032

免疫チェックポイント阻害剤の世界市場規模は2023年に431億米ドルに達した。今後、IMARC Groupは、市場が2032年までに1572億米ドルに達し、2024年から2032年の間に15.01%の成長率(CAGR)を示すと予測している。... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IMARC Services Private Limited.
アイマークサービス
2024年1月30日 US$3,899
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
145 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

免疫チェックポイント阻害剤の世界市場規模は2023年に431億米ドルに達した。今後、IMARC Groupは、市場が2032年までに1572億米ドルに達し、2024年から2032年の間に15.01%の成長率(CAGR)を示すと予測している。様々な癌の有病率の上昇、呼吸器疾患の増加、個別化された医薬品への嗜好の高まりは、市場を牽引する主な要因の一つである。

免疫チェックポイント阻害剤は、T細胞やがん細胞などの免疫系細胞によって作られる特定のタンパク質を阻害することで、がんの治療に利用される薬剤である。単独で、あるいは化学療法や放射線療法など他のがん治療と組み合わせて使用され、治療効果を高める。免疫チェックポイント阻害薬は、病気の症状を軽減し、生存期間を延長することで、がん患者の生活の質を高めるのに役立つ。免疫チェックポイント阻害剤は、免疫系の特定の経路を標的とするため、がん治療により的を絞ったアプローチが可能となる。これらの阻害剤は、従来の化学療法と比較して、副作用が少なく、患者の忍容性を高める低毒性プロファイルを持っている。現在、がん細胞内の特定の遺伝子変異の同定を可能にする次世代シーケンサー技術の利用が増加しており、これが世界中で免疫チェックポイント阻害剤の需要を喚起している。

免疫チェックポイント阻害剤の市場動向:
メラノーマ、肝臓がん、腎臓がん、胃がんなど、さまざまながんの罹患率が急増していることは、免疫チェックポイント阻害剤の需要を世界中で押し上げている主な要因のひとつである。さらに、このような重篤な癌を発症しやすい高齢化人口の増加や肥満の有病率の上昇が、市場の成長を後押ししている。さらに、アルコール飲料やタバコの消費量の増加により、呼吸器疾患の発生率が増加している。このことは、不健康な食習慣や座りがちなライフスタイルのために体重に関連した健康上の懸念が増加していることと相まって、市場にプラスの影響を与えている。これとは別に、様々な遺伝性疾患や生活習慣病の急増、癌の早期診断と早期治療の利点に関する個人や医療従事者の意識の高まりが、市場の成長を後押ししている。さらに、製薬企業による臨床試験の拡大、個別化医薬品や新世代の医薬品・製剤に対する嗜好の高まりが、市場の成長を後押ししている。これに加えて、製品ポートフォリオを拡大し競争優位性を獲得するために、大手企業が戦略的提携や新製品開発に注力する傾向が強まっていることも、市場に明るい展望をもたらしている。さらに、医療インフラと診断技術の大幅な向上が市場の成長を強化すると予想される。

主な市場セグメンテーション
IMARC Groupは、世界の免疫チェックポイント阻害薬市場の各セグメントにおける主要動向の分析と、2024年から2032年にかけての世界、地域、国レベルでの予測を提供しています。当レポートでは、市場をタイプ、流通チャネル、用途に基づいて分類しています。

タイプ別インサイト

CTLA-4阻害剤
PD-1阻害剤
PD-L1阻害剤

本レポートでは、免疫チェックポイント阻害剤市場をタイプ別に詳細に分類・分析している。これにはCTLA-4阻害剤、PD-1阻害剤、PD-L1阻害剤が含まれる。報告書によると、PD-1阻害剤が最大のセグメントを占めている。

流通チャネルの洞察

病院薬局
小売薬局
オンライン薬局

本レポートでは、免疫チェックポイント阻害剤市場を流通チャネル別に詳細に分類・分析しています。これには病院薬局、小売薬局、オンライン薬局が含まれる。報告書によると、病院薬局が最大の市場シェアを占めている。

アプリケーションの洞察

肺がん
膀胱がん
黒色腫
大腸がん
ホジキンリンパ腫
その他

本レポートでは、免疫チェックポイント阻害剤市場を用途別に詳細に分類・分析している。これには、肺がん、膀胱がん、メラノーマ、大腸がん、ホジキンリンパ腫、その他が含まれる。報告書によると、肺がんが最大のセグメントを占めている。

地域別の洞察

北米
米国
カナダ
アジア太平洋
中国
日本
インド
韓国
オーストラリア
インドネシア
その他
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
ロシア
その他
ラテンアメリカ
ブラジル
メキシコ
その他
中東・アフリカ

また、北米(米国、カナダ)、アジア太平洋(中国、日本、インド、韓国、オーストラリア、インドネシア、その他)、欧州(ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他)、中南米(ブラジル、メキシコ、その他)、中東・アフリカの主要地域市場についても包括的に分析している。報告書によると、免疫チェックポイント阻害剤の最大市場は北米である。北米の免疫チェックポイント阻害剤市場を牽引する要因としては、高齢化人口の増加、医療インフラの整備、研究開発(R&D)活動の活発化などが挙げられる。

競合情勢
本レポートでは、世界の免疫チェックポイント阻害剤市場における競争環境についても包括的に分析している。市場構造、主要企業による市場シェア、プレイヤーのポジショニング、上位の勝ち組戦略、競合ダッシュボード、企業評価象限などの競合分析が網羅されています。また、主要企業の詳細プロフィールも掲載しています。対象となる企業には、AstraZeneca plc、Bristol-Myers Squibb Company、GSK plc、Merck & Co.Inc.、小野薬品工業株式会社、ファイザー株式会社、AstraZeneca plc.小野薬品工業株式会社、ファイザー株式会社、Regeneron Pharmaceuticals Inc.

本レポートで回答した主な質問
1.免疫チェックポイント阻害剤の世界市場規模は?
2.2024年から2032年にかけての世界の免疫チェックポイント阻害薬市場の予想成長率は?
3.免疫チェックポイント阻害剤の世界市場を牽引する主要因は何か?
4.COVID-19が免疫チェックポイント阻害剤の世界市場に与えた影響は?
5.免疫チェックポイント阻害剤の世界市場におけるタイプ別の内訳は?
6.免疫チェックポイント阻害剤の世界市場における販売チャネル別の内訳は?
7.免疫チェックポイント阻害剤の世界市場の用途別内訳は?
8.免疫チェックポイント阻害剤の世界市場における主要地域は?
9.免疫チェックポイント阻害剤の世界市場における主要プレイヤー/企業は?

ページTOPに戻る


目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Immune Checkpoint Inhibitors Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 CTLA-4 Inhibitor
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 PD-1 Inhibitor
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 PD-L1 Inhibitor
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Lung Cancer
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Bladder Cancer
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Melanoma
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Colorectal Cancer
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Hodgkin Lymphoma
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AstraZeneca plc
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bristol-Myers Squibb Company
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 GSK plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Merck & Co. Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Ono Pharmaceutical Co. Ltd.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Pfizer Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Regeneron Pharmaceuticals Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Seagen Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis


List of Figures

Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2023
Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2023
Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2023
Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2023
Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2023
Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players

 

ページTOPに戻る


 

Summary

The global immune checkpoint inhibitors market size reached US$ 43.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 157.2 Billion by 2032, exhibiting a growth rate (CAGR) of 15.01% during 2024-2032. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:
The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, distribution channel, and application.

Type Insights:

CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Application Insights:

Lung Cancer
Bladder Cancer
Melanoma
Colorectal Cancer
Hodgkin Lymphoma
Others

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.

Key Questions Answered in This Report
1. How big is the global immune checkpoint inhibitors market?
2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2024-2032?
3. What are the key factors driving the global immune checkpoint inhibitors market?
4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
8. What are the key regions in the global immune checkpoint inhibitors market?
9. Who are the key players/companies in the global immune checkpoint inhibitors market?



ページTOPに戻る


Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Immune Checkpoint Inhibitors Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 CTLA-4 Inhibitor
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 PD-1 Inhibitor
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 PD-L1 Inhibitor
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Lung Cancer
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Bladder Cancer
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Melanoma
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Colorectal Cancer
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Hodgkin Lymphoma
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AstraZeneca plc
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bristol-Myers Squibb Company
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 GSK plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Merck & Co. Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Ono Pharmaceutical Co. Ltd.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Pfizer Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Regeneron Pharmaceuticals Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Seagen Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis


List of Figures

Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2023
Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2023
Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2023
Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2023
Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2023
Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

IMARC Services Private Limited. 社の最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


IMARC Services Private Limited.社はどのような調査会社ですか?


インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/09/20 10:26

143.76 円

160.81 円

193.57 円

ページTOPに戻る